A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs MORAb-202 (Primary)
- Indications Breast cancer; Endometrial cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Eisai Co Ltd
- 04 Jun 2019 Preliminary efficacy results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 25 May 2018 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 25 May 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History